Skip to content

Establishing a normal reference range for Thromboelastography in Chinese healthy Third trimester pregnant women volunteers

Establishing a normal reference range for Thromboelastography in Chinese healthy Third trimester pregnant women volunteers

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DRD-16007797
Enrollment
Unknown
Registered
2016-01-19
Start date
2016-01-20
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pregnant women

Interventions

Gold Standard:
Index test:

Sponsors

Blood transfusion department of The Affiliated third Hospital of the Third Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1) our hospital late single pregnancy pregnant; 2) Aged 18-45 years old; 3) gestational time: 28-40 weeks; 4) No merger medical illness; 5) No obstetric complications; 6) admission blood, liver and kidney function and routine coagulation detected no obvious abnormalities.

Exclusion criteria

Exclusion criteria: 1) the presence of fever or symptoms of infection; 2) coagulation disorder or thrombotic disease history; 3) used within 30 days of anticoagulant or antiplatelet drugs; 4) six months have used hormonal contraceptives; 5) 6 months experienced childbirth or abortion; 6) The merger of other obstetrical complications such as preeclampsia, pregnancy late diabetic, pregnant late merger blood complicated with small plates reduce psychosis; 7) for check fetal abnormalities or appendages; 8) unwilling participants.

Design outcomes

Primary

MeasureTime frame
Thromboelastogram;

Secondary

MeasureTime frame
Coagulation detection related indicators;

Countries

China

Contacts

Public ContactWen Aiqing
dpyysxkwaq@hotmail.com+86 023-68757651

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026